B

Banyan Corp
OTC:BNYN

Watchlist Manager
Banyan Corp
OTC:BNYN
Watchlist
Price: 0.0002 USD Market Closed
Market Cap: $290.6k

Banyan Corp
Other Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Banyan Corp
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
B
Banyan Corp
OTC:BNYN
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CVS Health Corp
NYSE:CVS
Other Receivables
$29.2B
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cigna Corp
NYSE:CI
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Laboratory Corporation of America Holdings
NYSE:LH
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Guardant Health Inc
NASDAQ:GH
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Banyan Corp
Glance View

Market Cap
290.6k USD
Industry
Health Care

Banyan Corp. is a holding company which engages in investing in medical, and diagnostic imaging business. The company is headquartered in Los Angeles, California and currently employs 20 full-time employees. The company went IPO on 2001-06-21. The firm has franchise agreements covering 55 locations. These franchise agreements provide for payment of percentage royalties, contribution to an advertising fund, and charges for additional services selected by the franchisee. Some franchise agreements cover more than one location.

BNYN Intrinsic Value
Not Available
B

See Also

What is Banyan Corp's Other Receivables?
Other Receivables
0 USD

Based on the financial report for Dec 31, 2007, Banyan Corp's Other Receivables amounts to 0 USD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett